Molecular Discovery Platform

The CeMM Molecular Discovery Platform empowers the discovery and characterization of bioactive molecules, including proteins, metabolites, and novel synthetic compounds. State-of-the art instrumentation and scientific expertise in liquid chromatography-mass spectrometry, high-throughput screening and high-content analysis underlies the technology-driven approach.

The Molecular Discovery Platform consists of three facilities:

The three facilities implement and innovate in selected projects the latest technologies in their respective fields. They synergize towards the common goal of using automation for maximizing data output from minimal biological sample amounts.

The platform aims at contributing initial starting points towards the discovery of new therapies. It is accessible to all research groups at CeMM as well as external collaborators.

Stefan Kubicek
Head of Molecular Discovery Platform


Stefan Kubicek, born in 1978, is Austrian and joined CeMM in August 2010. He obtained an MSc in synthetic organic chemistry from the Vienna University of Technology after writing a diploma thesis at ETH Zurich. For his PhD in Thomas Jenuwein’s lab at the IMP in Vienna, he changed fields to molecular biology. He then performed postdoctoral research working on chemical biology with Stuart Schreiber at the Broad Institute of Harvard and MIT. Stefan Kubicek heads the chemical screening platform and PLACEBO (Platform Austria for Chemical Biology), a task he is well equipped for based on previous screening experience with Boehringer Ingelheim and at the Broad Institute. These activities have resulted in the identification of the first selective histone methyl transferase inhibitors and small molecule inducers of insulin expression. Stefan Kubicek has also headed the Christian Doppler Laboratory for Chemical Epigenetics and Antiinfectives, a public-private partnership between CeMM, Boehringer Ingelheim and Haplogen. The Kubicek lab is working on the role of chromatin in the definition of cell types and cell states, particularly chromatin-modifying enzymes as synthetic lethal targets in cancer and chemical transdifferentiation to insulin-producing beta cells. In an ERC-funded project, the laboratory is working on metabolic enzymes in the cell’s nucleus and testing the hypothesis that small molecule metabolites shape chromatin structure and thus control gene expression and cell identity.